产品
编 号：F302366
分子式：C12H11ClN6O2S2
分子量：370.84
分子式：C12H11ClN6O2S2
分子量：370.84
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 27589-33-9
产品详情
生物活性：
Azosemide, a sulfonamide loop diuretic, is a potent NKCC1 inhibitor with IC50s of 0.246?μM and 0.197?μM for hNKCC1A and NKCC1B, respectively.
体内研究：
Azosemide shows a smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NARs.Animal Model:Male Sprague-Dawley rats (control rats, weighing 310345 g) and NARs (weighing 220315 g) of 9 weeks of age
Dosage:10 mg/kg (Pharmacokinetic Analysis)
Administration:Infused over 1 min via the jugular vein (i.v.)
Result:Showed a smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NARs.
体外研究：
Azosemide inhibits the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
Azosemide, a sulfonamide loop diuretic, is a potent NKCC1 inhibitor with IC50s of 0.246?μM and 0.197?μM for hNKCC1A and NKCC1B, respectively.
体内研究：
Azosemide shows a smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NARs.Animal Model:Male Sprague-Dawley rats (control rats, weighing 310345 g) and NARs (weighing 220315 g) of 9 weeks of age
Dosage:10 mg/kg (Pharmacokinetic Analysis)
Administration:Infused over 1 min via the jugular vein (i.v.)
Result:Showed a smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NARs.
体外研究：
Azosemide inhibits the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备